PHARMACY

Thrifty White, PrescribeWellness expand offering to affiliated pharmacy partners
Thrifty White will be expanding its partnership with pharmacy technology company PrescribeWellness, offering it to the Plymouth, Minn.-based chain’s independently owned pharmacy partners through Thrifty White's Affiliated Pharmacy Program.
Sun Pharma gets FDA green light for generic Glumetza tablets
Sun Pharma's generic version of Glumetza is intended to improve glycemic control in adults with Type 2 diabetes.

Senate panel passes bill to end “gag clauses”

NACDS lauds Senate panel's action on bill to end gag clauses in contracts between health plans and pharmacies.
CVS Health addresses rising prescription drug costs at Politico meeting

At a recent Politico Pro Summit event, CVS Health’s Tom Moriarty addressed the rising cost of prescription drugs and outlined market-based strategies to promote competition and make medications more affordable.
AbbVie gets FDA nod for Orilissa

Developed in collaboration with Neurocrine Biosciences, Orilissa is the first and only oral gonadotropin-releasing hormone antagonist specifically developed for women with moderate to severe endometriosis pain, AbbVie said.
AllianceRx Walgreens Prime earns URAC home delivery accreditation

AllianceRx Walgreens Prime was formed in 2017 through a collaboration between Walgreens and Prime Therapeutics, a leading pharmacy benefit manager.
AAM: Most generic scripts filled at $20 or less

The Association for Accessible Medicines recently released its Generic Access and Savings Report in the United States 2018, which found that 93% of generic prescriptions are filled at $20 or less, and the average co-pay for a generic drug to be $6.06.
Pfizer gains FDA nod for Neupogen biosimilar Nivestym

Pfizer has received Food and Drug Administration approval for Nivestym (filgrastim-aafi), a biosimilar to Neupogen (filgrastim).
FDA approves Amneal’s generic potassium chloride

Potassium chloride oral solution had a market value of approximately $185 million for the 12 months ending May 2018, according to IQVIA data.
FDA urges development of opioid analgesic products that deter abuse

In an effort to address the opioid epidemic, the Food and Drug Administration is urging the development of opioid analgesic products that are harder to manipulate and abuse.